Jul 19, 2021
Vivpro Announces New Appointment To Board Of Advisors: Mr. Amit Kohli
Vivpro Corporation announced today that it has appointed Mr. Amit Kohli, CEO of Antev Ltd to its Advisory Board.
”We continue our exciting growth journey with Mr. Kohli’s addition to the advisory board and look forward to working with him to deliver value to pharmaceutical and biotech stakeholders,” said Dr. Joga Gobburu, President Vivpro Corporation. ”Amit has unique experience throughout the lifecycle of pharmaceutical and biotech industry. We hope to leverage his experience to Vivpro further the mission to re-imagine drug development. Amit is a founding member of the Vivpro Advisory Board. Vivpro Advisory Board is a critical step in our journey as we enter a new stage of product growth, we would like to work with passionate individuals like Amit to validate and guide our niche market strategy and customer value.”
This is one of several appointments that will be announced over the next few weeks. Vivpro will regularly evaluate the membership to ensure it includes diverse skills, experience and perspective necessary to drive growth for all Vivpro customers.
”Vivpro is using state-of-the-art technology platform and deep drug development & regulatory expertise to simplify access to the regulatory inputs in clinical development and approval pathway to the benefit of pharmaceutical industry, innovative biotech, life science investors and researchers. I look forward to contribute to the success of the talented Vivpro team,” said Mr. Amit Kohli.
About Mr. Amit Kohli
Amit Kohli is Chief Executive Officer of Antev Ltd. Mr. Kohli is responsible for leading Antev's corporate strategy and operational and clinical development and will oversee the Company's advance along the clinical pathway towards commercialization for its lead indication, teverelix, anovel gonadotrophin releasing hormone (”GnRH”) antagonist for the treatment of hormone sensitive advanced prostate cancer.
Before joining Antev, Mr Kohli was Chief Operating Officer at Pharnext SA (”Pharnext”), a Euronext listed advanced clinical-stage biopharmaceutical company, developing novel therapeutics for orphan neurodegenerative disorders. At Pharnext, Mr Kohli was responsible for leading corporate strategy and operations
Prior to Pharnext, Mr Kohli held leadership roles at Eurofins, Becton Dickinson and at Sanofi, encompassing sales, marketing, supply chain and manufacturing.
Mr. Kohli earned an M.B.A. from the Management Development Institute (MDI) Gurgaon, in India and a Bachelor of Engineering from the University of Pune in India.
